| Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 … W Taal, HM Oosterkamp, AME Walenkamp, HJ Dubbink, LV Beerepoot, ... The lancet oncology 15 (9), 943-953, 2014 | 887 | 2014 |
| A review on CXCR4/CXCL12 axis in oncology: no place to hide UM Domanska, RC Kruizinga, WB Nagengast, H Timmer-Bosscha, ... European journal of cancer 49 (1), 219-230, 2013 | 742 | 2013 |
| Rectal and colon cancer: Not just a different anatomic site K Tamas, AME Walenkamp, EGE De Vries, M Van Vugt, RG Beets-Tan, ... Cancer treatment reviews 41 (8), 671-679, 2015 | 377 | 2015 |
| Value of 11C-methionine PET in imaging brain tumours and metastases AWJM Glaudemans, RH Enting, MAAM Heesters, RAJO Dierckx, ... European journal of nuclear medicine and molecular imaging 40, 615-635, 2013 | 326 | 2013 |
| Glioma progression is shaped by genetic evolution and microenvironment interactions FS Varn, KC Johnson, J Martinek, JT Huse, MLP Nasrallah, P Wesseling, ... Cell 185 (12), 2184-2199. e16, 2022 | 289 | 2022 |
| Predictors of adherence to exercise interventions during and after cancer treatment: a systematic review HL Ormel, GGF Van Der Schoot, WJ Sluiter, M Jalving, JA Gietema, ... Psycho‐oncology 27 (3), 713-724, 2018 | 259 | 2018 |
| Clinical and therapeutic aspects of extrapulmonary small cell carcinoma AME Walenkamp, GS Sonke, DT Sleijfer Cancer treatment reviews 35 (3), 228-236, 2009 | 242 | 2009 |
| CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy UM Domanska, H Timmer-Bosscha, WB Nagengast, THO Munnink, ... Neoplasia 14 (8), 709-718, 2012 | 239 | 2012 |
| Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis ME Van Linde, CG Brahm, PC de Witt Hamer, JC Reijneveld, ... Journal of neuro-oncology 135, 183-192, 2017 | 211 | 2017 |
| TGF-β is an inducer of ZEB1-dependent mesenchymal transdifferentiation in glioblastoma that is associated with tumor invasion JV Joseph, S Conroy, T Tomar, E Eggens-Meijer, K Bhat, S Copray, ... Cell death & disease 5 (10), e1443-e1443, 2014 | 207 | 2014 |
| TGF-β as a therapeutic target in high grade gliomas–promises and challenges JV Joseph, V Balasubramaniyan, A Walenkamp, FAE Kruyt Biochemical pharmacology 85 (4), 478-485, 2013 | 195 | 2013 |
| INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma M Van Den Bent, M Eoli, JM Sepulveda, M Smits, A Walenkamp, ... Neuro-oncology 22 (5), 684-693, 2020 | 186 | 2020 |
| CXCR4 ligands: the next big hit? AME Walenkamp, C Lapa, K Herrmann, HJ Wester Journal of Nuclear Medicine 58 (Supplement 2), 77S-82S, 2017 | 161 | 2017 |
| Internet-based support programs to alleviate psychosocial and physical symptoms in cancer patients: a literature analysis G Bouma, JM Admiraal, EGE de Vries, CP Schröder, AME Walenkamp, ... Critical reviews in oncology/hematology 95 (1), 26-37, 2015 | 122 | 2015 |
| A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management K Oberg, E Krenning, A Sundin, L Bodei, M Kidd, M Tesselaar, ... Endocrine connections 5 (5), 174-187, 2016 | 121 | 2016 |
| Staphylococcal SSL5 inhibits leukocyte activation by chemokines and anaphylatoxins J Bestebroer, KPM van Kessel, H Azouagh, AM Walenkamp, IGJ Boer, ... Blood, The Journal of the American Society of Hematology 113 (2), 328-337, 2009 | 121 | 2009 |
| Identification of patients with recurrent glioblastoma who may benefit from combined bevacizumab and CCNU therapy: a report from the BELOB trial L Erdem-Eraslan, MJ van den Bent, Y Hoogstrate, H Naz-Khan, A Stubbs, ... Cancer research 76 (3), 525-534, 2016 | 111 | 2016 |
| TGF-β antibody uptake in recurrent high-grade glioma imaged with 89Zr-fresolimumab PET MW den Hollander, F Bensch, AWJM Glaudemans, THO Munnink, ... Journal of Nuclear Medicine 56 (9), 1310-1314, 2015 | 110 | 2015 |
| Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer I Heidegger, G Fotakis, A Offermann, J Goveia, S Daum, S Salcher, ... Molecular cancer 21 (1), 132, 2022 | 101 | 2022 |
| Staphylococcal superantigen-like 10 inhibits CXCL12-induced human tumor cell migration AME Walenkamp, IGJ Boer, J Bestebroer, D Rozeveld, ... Neoplasia 11 (4), 333-344, 2009 | 101 | 2009 |
